- Home
- VCNX vs CWD Comparison
VCNX vs CWD Comparison
Compare VCNX & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCNX
- CWD
- Stock Information
- Founded
- VCNX 2001
- CWD 2009
- Country
- VCNX United States
- CWD United States
- Employees
- VCNX N/A
- CWD N/A
- Industry
- VCNX Biotechnology: Pharmaceutical Preparations
- CWD Real Estate
- Sector
- VCNX Health Care
- CWD Finance
- Exchange
- VCNX Nasdaq
- CWD Nasdaq
- Market Cap
- VCNX 10.5M
- CWD 10.0M
- IPO Year
- VCNX N/A
- CWD 2023
- Fundamental
- Price
- VCNX $1.41
- CWD $0.50
- Analyst Decision
- VCNX
- CWD
- Analyst Count
- VCNX 0
- CWD 0
- Target Price
- VCNX N/A
- CWD N/A
- AVG Volume (30 Days)
- VCNX 96.1K
- CWD 70.9K
- Earning Date
- VCNX 11-14-2024
- CWD 11-12-2024
- Dividend Yield
- VCNX N/A
- CWD N/A
- EPS Growth
- VCNX N/A
- CWD N/A
- EPS
- VCNX N/A
- CWD N/A
- Revenue
- VCNX $388,000.00
- CWD $66,376,999.00
- Revenue This Year
- VCNX N/A
- CWD N/A
- Revenue Next Year
- VCNX N/A
- CWD $38.91
- P/E Ratio
- VCNX N/A
- CWD N/A
- Revenue Growth
- VCNX N/A
- CWD N/A
- 52 Week Low
- VCNX $1.25
- CWD $0.37
- 52 Week High
- VCNX $13.02
- CWD $1.50
- Technical
- Relative Strength Index (RSI)
- VCNX 27.23
- CWD 46.14
- Support Level
- VCNX $3.34
- CWD $0.49
- Resistance Level
- VCNX $4.35
- CWD $0.52
- Average True Range (ATR)
- VCNX 0.45
- CWD 0.04
- MACD
- VCNX -0.19
- CWD 0.01
- Stochastic Oscillator
- VCNX 0.00
- CWD 60.00
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.